CN102131483A - 可控给药非聚合组合物 - Google Patents

可控给药非聚合组合物 Download PDF

Info

Publication number
CN102131483A
CN102131483A CN2009801120239A CN200980112023A CN102131483A CN 102131483 A CN102131483 A CN 102131483A CN 2009801120239 A CN2009801120239 A CN 2009801120239A CN 200980112023 A CN200980112023 A CN 200980112023A CN 102131483 A CN102131483 A CN 102131483A
Authority
CN
China
Prior art keywords
acid
composition
biologically active
composition according
hormone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801120239A
Other languages
English (en)
Chinese (zh)
Inventor
李雨华
安德鲁·郭瑞诺
简铭达
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yat Biological Polytron Technologies Inc
Original Assignee
QPS LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by QPS LLC filed Critical QPS LLC
Publication of CN102131483A publication Critical patent/CN102131483A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2009801120239A 2008-02-08 2009-02-05 可控给药非聚合组合物 Pending CN102131483A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6517808P 2008-02-08 2008-02-08
US61/065,178 2008-02-08
PCT/US2009/033226 WO2009100222A1 (en) 2008-02-08 2009-02-05 Non-polymeric compositions for controlled drug delivery

Publications (1)

Publication Number Publication Date
CN102131483A true CN102131483A (zh) 2011-07-20

Family

ID=40952458

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801120239A Pending CN102131483A (zh) 2008-02-08 2009-02-05 可控给药非聚合组合物

Country Status (8)

Country Link
US (1) US8586103B2 (enExample)
EP (1) EP2244679A4 (enExample)
JP (1) JP5737949B2 (enExample)
CN (1) CN102131483A (enExample)
AU (1) AU2009212373B2 (enExample)
CA (1) CA2714514C (enExample)
TW (1) TWI400090B (enExample)
WO (1) WO2009100222A1 (enExample)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102961362A (zh) * 2012-12-03 2013-03-13 上海应用技术学院 一种β-聚苹果酸/壳聚糖纳米药物缓释微胶囊及其制备方法
CN104721809A (zh) * 2015-03-12 2015-06-24 内蒙古金河动物药业有限公司 一种包含硫酸黏菌素的药物组合物及其制备方法
CN105142730A (zh) * 2013-03-15 2015-12-09 通尼克斯制药有限公司 环苯扎林盐酸盐和阿米替林盐酸盐的低共熔混合物配制剂
CN105727260A (zh) * 2016-02-03 2016-07-06 华侨大学 一种卵泡刺激素的长效制剂
CN107073129A (zh) * 2014-09-10 2017-08-18 双键医药品股份公司 亲水性药物的靶向递送
CN107173664A (zh) * 2017-04-27 2017-09-19 南昌大学 一种提高乳状液稳定性的没食子酸月桂酯复合抗氧化剂
CN109310680A (zh) * 2016-06-30 2019-02-05 度瑞公司 长效配制物
CN111388406A (zh) * 2020-03-24 2020-07-10 西安力邦医药科技有限责任公司 氟维司群或其衍生物可注射递药贮库及其制备方法和应用
CN112806359A (zh) * 2020-12-30 2021-05-18 河北威远生物化工有限公司 一种生物可降解型农药缓释乳油及其制备方法和应用
CN113368041A (zh) * 2020-07-17 2021-09-10 丽珠医药集团股份有限公司 药物组合物、缓释制剂及其制备方法
WO2022193975A1 (zh) * 2021-03-16 2022-09-22 湖南慧泽生物医药科技有限公司 供注射用罗哌卡因长效溶液制剂及其制备方法
CN116421578A (zh) * 2023-03-31 2023-07-14 辉粒药业(苏州)有限公司 生长抑素类似物缓释微球及其制备方法

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
CA2686137C (en) 2007-05-18 2021-01-12 Durect Corporation Improved depot formulations
EP2152315B1 (en) 2007-05-25 2016-01-06 Indivior UK Limited Sustained delivery formulations of risperidone compounds
AU2009212367B2 (en) * 2008-02-08 2013-08-01 Foresee Pharmaceuticals Co., Ltd. Composition for sustained release delivery of proteins or peptides
WO2010133961A1 (en) 2009-05-22 2010-11-25 Inventia Healthcare Private Limited Extended release compositions of cyclobenzaprine
IE20100174A1 (en) * 2010-03-25 2012-02-29 Trinity College Dublin Transdermal administration of peptides
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US11998516B2 (en) 2011-03-07 2024-06-04 Tonix Pharma Holdings Limited Methods and compositions for treating depression using cyclobenzaprine
KR101494594B1 (ko) 2011-08-30 2015-02-23 주식회사 종근당 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
KR101586789B1 (ko) * 2012-12-28 2016-01-19 주식회사 종근당 양이온성 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
KR101586791B1 (ko) 2012-12-28 2016-01-19 주식회사 종근당 ＧｎＲＨ 유도체의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
US20140308352A1 (en) 2013-03-11 2014-10-16 Zogenix Inc. Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material
BR112015022023B1 (pt) 2013-03-11 2022-12-06 Durect Corporation Composição de liberação controlada injetável compreendendo transportador líquido de alta viscosidade
CN105764491A (zh) 2013-12-09 2016-07-13 度瑞公司 药物活性剂复合物、聚合物复合物，以及包括其的组合物和方法
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
WO2016046673A1 (en) * 2014-09-28 2016-03-31 Mohan M Alapati Compositions and methods for the treatment of neurological diseases
US10744070B2 (en) 2015-06-19 2020-08-18 University Of Southern California Enteral fast access tract platform system
CA2990230A1 (en) 2015-06-19 2016-12-22 University Of Southern California Compositions and methods for modified nutrient delivery
US20210186879A1 (en) * 2016-03-07 2021-06-24 Double Bond Pharmaceuticals Ab Targeted delivery of hydrophilic drugs to lung
US10682340B2 (en) * 2016-06-30 2020-06-16 Durect Corporation Depot formulations
EA201990127A1 (ru) * 2016-12-30 2020-08-18 Дьюрект Корпорейшн Депо-препарат
WO2019116091A1 (en) 2017-12-11 2019-06-20 Tonix Pharma Holdings Limited Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
EP3620494A1 (en) 2018-09-06 2020-03-11 Holland Novochem Technical Coatings B.V. Rheology modifier and compatibilizer
CN115666571B (zh) * 2020-05-20 2024-11-05 美德阿利克斯株式会社 含有阿扑吗啡的经皮吸收型制剂
EP4282435A1 (en) * 2022-05-23 2023-11-29 Danmarks Tekniske Universitet Formulations of active pharmaceutical ingredients and excipients in icells via hydrophobic ion pairing
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3932610A (en) * 1971-12-06 1976-01-13 Lever Brothers Company Shampoo composition
AU5171293A (en) 1992-10-14 1994-05-09 Regents Of The University Of Colorado, The Ion-pairing of drugs for improved efficacy and delivery
JP4330175B2 (ja) * 1995-06-07 2009-09-16 デュレクト コーポレイション 高粘度液体による制御された送達系
US5747058A (en) 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US5968542A (en) 1995-06-07 1999-10-19 Southern Biosystems, Inc. High viscosity liquid controlled delivery system as a device
US6413536B1 (en) * 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
JPH10218745A (ja) * 1997-02-12 1998-08-18 Rashieru Seiyaku Kk シャンプー組成物
US6051558A (en) 1997-05-28 2000-04-18 Southern Biosystems, Inc. Compositions suitable for controlled release of the hormone GnRH and its analogs
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
EP1073419A4 (en) * 1998-03-18 2009-03-25 Univ Technology Corp COMPOSITION, CONTAINING AMORPHOUS POLYMER, FOR DELAYED RELEASE.
US6992065B2 (en) 2000-04-19 2006-01-31 Genentech, Inc. Sustained release formulations
DE10312346A1 (de) * 2003-03-20 2004-09-30 Bayer Healthcare Ag Kontrolliertes Freisetzungssystem
CA2532302C (en) * 2003-07-15 2016-12-20 Pr Pharmaceuticals, Inc. Method for the preparation of controlled release formulations
CA2581287C (en) * 2004-09-17 2015-08-25 Durect Corporation Sustained local anesthetic composition containing bupivacaine and saib

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102961362B (zh) * 2012-12-03 2014-07-30 上海应用技术学院 一种β-聚苹果酸/壳聚糖纳米药物缓释微胶囊及其制备方法
CN102961362A (zh) * 2012-12-03 2013-03-13 上海应用技术学院 一种β-聚苹果酸/壳聚糖纳米药物缓释微胶囊及其制备方法
CN105142730A (zh) * 2013-03-15 2015-12-09 通尼克斯制药有限公司 环苯扎林盐酸盐和阿米替林盐酸盐的低共熔混合物配制剂
CN110152005B (zh) * 2013-03-15 2023-08-04 通尼克斯制药控股有限公司 环苯扎林盐酸盐和阿米替林盐酸盐的低共熔混合物配制剂
CN110152005A (zh) * 2013-03-15 2019-08-23 通尼克斯制药有限公司 环苯扎林盐酸盐和阿米替林盐酸盐的低共熔混合物配制剂
US10973772B2 (en) 2014-09-10 2021-04-13 Double Bond Pharmaceuticals Ab Targeted delivery of hydrophilic drugs
CN107073129A (zh) * 2014-09-10 2017-08-18 双键医药品股份公司 亲水性药物的靶向递送
CN107073129B (zh) * 2014-09-10 2021-10-15 双键医药品股份公司 亲水性药物的靶向递送
CN104721809A (zh) * 2015-03-12 2015-06-24 内蒙古金河动物药业有限公司 一种包含硫酸黏菌素的药物组合物及其制备方法
CN105727260A (zh) * 2016-02-03 2016-07-06 华侨大学 一种卵泡刺激素的长效制剂
CN109310680A (zh) * 2016-06-30 2019-02-05 度瑞公司 长效配制物
CN109310680B (zh) * 2016-06-30 2022-11-01 度瑞公司 长效配制物
CN107173664A (zh) * 2017-04-27 2017-09-19 南昌大学 一种提高乳状液稳定性的没食子酸月桂酯复合抗氧化剂
CN111388406A (zh) * 2020-03-24 2020-07-10 西安力邦医药科技有限责任公司 氟维司群或其衍生物可注射递药贮库及其制备方法和应用
CN111388406B (zh) * 2020-03-24 2024-02-23 西安力邦医药科技有限责任公司 氟维司群或其衍生物可注射递药贮库及其制备方法和应用
CN113368041A (zh) * 2020-07-17 2021-09-10 丽珠医药集团股份有限公司 药物组合物、缓释制剂及其制备方法
CN112806359A (zh) * 2020-12-30 2021-05-18 河北威远生物化工有限公司 一种生物可降解型农药缓释乳油及其制备方法和应用
WO2022193975A1 (zh) * 2021-03-16 2022-09-22 湖南慧泽生物医药科技有限公司 供注射用罗哌卡因长效溶液制剂及其制备方法
CN116421578A (zh) * 2023-03-31 2023-07-14 辉粒药业(苏州)有限公司 生长抑素类似物缓释微球及其制备方法

Also Published As

Publication number Publication date
JP2011511088A (ja) 2011-04-07
US8586103B2 (en) 2013-11-19
JP5737949B2 (ja) 2015-06-17
AU2009212373A2 (en) 2011-02-17
US20100034801A1 (en) 2010-02-11
EP2244679A4 (en) 2013-10-09
AU2009212373A1 (en) 2009-08-13
EP2244679A1 (en) 2010-11-03
CA2714514C (en) 2016-08-16
WO2009100222A1 (en) 2009-08-13
AU2009212373B2 (en) 2013-10-03
TW200936167A (en) 2009-09-01
TWI400090B (zh) 2013-07-01
CA2714514A1 (en) 2009-08-13

Similar Documents

Publication Publication Date Title
AU2009212373B2 (en) Non-polymeric compositions for controlled drug delivery
US10646572B2 (en) Pharmaceutical compositions with enhanced stability
EP2054073B1 (en) Pharmaceutical compositions for sustained release delivery of peptides
CA2714506C (en) Composition for sustained release delivery of proteins or peptides
AU2005271242B9 (en) Pharmaceutical compositions for controlled release delivery of biologically active compounds
JP2011511088A5 (enExample)
HK1162295A (en) Non-polymeric compositions for controlled drug delivery

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1162295

Country of ref document: HK

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20150915

Address after: Taipei City, Taiwan, China

Applicant after: Yat biological Polytron Technologies Inc

Address before: The United States of Newark City

Applicant before: Qps LLC

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20110720

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1162295

Country of ref document: HK